{
    "2018-03-20": [
        [
            {
                "time": "",
                "original_text": "欧普康视持股5%以上股东减持198万股",
                "features": {
                    "keywords": [
                        "欧普康视",
                        "持股5%以上",
                        "股东减持",
                        "198万股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "[优异评级] 医药生物行业研究简报：国务院机构改革方案亮相 注射剂研发技术指导意见发布",
                "features": {
                    "keywords": [
                        "医药生物",
                        "国务院",
                        "机构改革",
                        "注射剂研发",
                        "技术指导意见"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}